-
Mashup Score: 4Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer - 8 hour(s) ago
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer - 4 day(s) ago
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer. @CWRUSOM @SABCSSanAntonio #SABCS24 #BCSM #oncology #MedTwitter https://t.co/Lg4mWHfYcr
-
-
Mashup Score: 2
Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer. @SABCSSanAntonio #SABCS24 #bcsm #oncology #MedTwitter https://t.co/FUQQIgtVSA
-
-
Mashup Score: 3
Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Neoadjuvant data for the antibody-drug conjugate SHR-A1811 highlight the potential role for the use of this class of agents in patients with early-stage HER2-positive breast cancer. @SABCSSanAntonio #SABCS24 #bcsm #oncology #MedTwitter https://t.co/RjY0aDieaD https://t.co/MPvJZHvvet
-
Zanidatamab-hrii has a novel mechanism of action and shows initial signals of clinical activity when combined with evorpacept in patients with HER2-positive breast cancer. @CWRUSOM @SABCSSanAntonio #SABCS24 #BCSM #oncology #MedTwitter https://t.co/zOekkhoToF https://t.co/iCWbZDymCU